Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

"Sanofi to increase competition in atopic dermatitis market after Dupixent success" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.